Compare Novartis AG (NVS) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.21 (market cap $4.35B). The key difference: Novartis AG is far larger — about 61.7× State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF's market cap, and Novartis AG pays a 3.31% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days on average.
| NVS | SJNK | |
|---|---|---|
Market Cap | $268.57B | $4.35B |
Volume | 1,532,573 | 3,211,044 |
Sector | Health | Fixed Income |
52-Week High | $168.62 | $25.57 |
52-Week Low | $121.80 | $24.13 |
Typical Hold Time | 82 Days | 41 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
SJNK, the SPDR Bloomberg Short Term High Yield Bond ETF, trades at $24.18 with a slight 24-hour decline of 0.08%. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF has maintained consistent dividend payments recently, with three distributions of $0.14-$0.15 scheduled for late 2026. Institutional activity shows mixed sentiment with Cetera Investment Advisers and Balefire LLC reducing positions in recent quarters.
The ETF faces headwinds from the current bearish technical setup while offering yield advantages over Treasury securities. Key risks include interest rate sensitivity and high-yield bond market volatility. Investors should weigh the attractive dividend yield against the technical weakness and institutional selling pressure when considering position sizing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
